Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older
Prior exposure to at least 1 line of therapy
Exposure to a including checkpoint inhibitor in line of therapy immediately prior to enrollment on trial
ECOG PS 0-2
You may not be if
Presence of a driver mutation that is susceptible to targeted therapy
No greater than CTCAE v5 grade 3 toxicity attributed to prior immunotherapy
Other active invasive malignancy requiring ongoing therapy
Evidence of progressing or untreated brain metastases
Evidence or history of leptomeningeal disease
Uncontrolled tumor related pain
History of an autoimmune disease or IPF
Clareo Health | Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
